China Zoster Vaccine Market Survey Report


Dublin, June 08, 2021 (GLOBE NEWSWIRE) — The “Chinese Zoster Vaccine Market Survey Report 2021-2025” report has been added to from offer.

The commercial name of the shingles vaccine is SHINGRIX, which was developed by GlaxoSmithKline. Its product was first approved in China in 2020.

The recombinant shingles vaccine is suitable for adults aged 50 and over to protect against shingles (herpes zoster). The recombinant shingles vaccine has been listed on the Chinese market. As of 2020, GlaxoSmithKline Biologicals is the only manufacturer in China’s shingles vaccine market.

According to the market researcher, since Shingles Vaccine entered the Chinese market in 2020, its annual sales value has reached CNY 2 million and its annual sales volume has reached 1,745 doses. The prospects for development are therefore quite good.

According to the analysis, from 2021 to 2025, as the shingles vaccine market expands, its sales will continue to grow. Compared with Merck’s Zostavax, SHINGRIX has better preventive effects and faster replacement speed. Therefore, as the Shingles Vaccine market share will gradually increase, the sales and sales volume will also increase.

Topics Covered:

  • The impact of COVID-19 on China’s shingles vaccine market
  • Sales value of shingles vaccine in China 2016-2020
  • Competitive Landscape of China Zoster Vaccine Market
  • shingles vaccine price in china
  • Shingles Vaccine Price in China by Regions and Manufacturers
  • Analysis of factors affecting the development of the Chinese shingles vaccine market
  • China Zoster Vaccine Market Outlook 2021 to 2025

Main topics covered:

1 Relevant shingles vaccine concept
1.1 Indications for shingles vaccine
1.2 Zoster Vaccine Development in China
1.3 Government approval of shingles vaccine in China
1.4 The impact of COVID-19 on Herpes Zoster Vaccine Sales in China

2 sales of shingles vaccine in China in 2020
2.1 Zoster Vaccine Sales Value
2.1.1 Overall sales value
2.1.2 Sales Value by Regions
2.2 Herpes Zoster Vaccine Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 China Herpes Zoster Vaccine Sales by Dosage Form in 2020
2.3.1 Injection
2.3.2 Analysis of other dosage forms

3 Analysis of Key Manufacturers of Herpes Zoster Vaccines in China in 2020
3.1 Herpes Zoster Vaccine Major Manufacturers Market Share Analysis
3.1.1 Market Share Survey by Sales Value
3.1.2 Market Share Survey by Sales Volume
3.2 Glaxo SmithKline Biologicals
3.2.1 Company profile
3.2.2 SHINGRIX (Glaxo SmithKline Biologicals Shingles Vaccine) Sales in China

4 Shingles Vaccine Price for Different Manufacturers in China, 2020-2021
4.1 Glaxo SmithKline Biologicals (SHINGRIX)

5 China Zoster Vaccine Market Outlook, 2021-2025
5.1 Influencing Factors on the Development of China Zoster Vaccine Market
5.1.1 The impact of COVID-19 on the Chinese shingles vaccine market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast

Companies cited

  • GlaxoSmithKline Biologicals
  • Merck

For more information on this report, visit


Comments are closed.